Citable filing context
ARE's research view summarizes recent SEC filing context, starting with debt_offering from Aug 14, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 14, 2026 | debt_offering | Alexandria Real Estate Equities priced $1 billion of 7.250% Series A junior subordinated notes due 2057. |
| Aug 3, 2026 | earnings | Alexandria Real Estate Equities reported financial results for the second quarter ended June 30, 2026. |
| Jul 9, 2026 | debt_offering | Alexandria Real Estate Equities entered into an escrow agreement for a $5 billion unsecured senior revolving credit facility. |
| Aug 3, 2026 | Guidance: ffo_per_share_diluted_as_adjusted | 6.35 to 6.45 |
| Aug 3, 2026 | Guidance: fixed_charge_coverage_ratio | 3.60 to 4.10 |
| Aug 3, 2026 | Guidance: net_debt_and_preferred_stock_to_adjusted_ebitda | 5.60 to 6.20 |
| Aug 3, 2026 | mda_quarterly | Alexandria Real Estate Equities (ARE) is navigating a challenging environment characterized by a significant supply-demand imbalance in the life science real estate sector. As of June 30, 2026, the company reports an operating occupancy of 86.9%, with same-property net operating income declining 10.6% year-over-year. This pressure stems from a surge in laboratory supply—driven by pandemic-era conversions and speculative development—colliding with moderated tenant demand, which has fallen over 60% from 2021 peaks across its core Greater Boston, San Diego, and San Francisco Bay Area markets. To manage these headwinds, ARE is executing a capital recycling strategy, targeting $2.9 billion in dispositions and partial interest sales for 2026 to fund development and reduce leverage. The company maintains a strong balance sheet with a 9.7-year weighted-average debt maturity and $3.6 billion in liquidity. Operational adjustments include pivoting some redevelopment projects, such as 3000 Minuteman Road, toward lower-cost advanced technology use to reduce construction budgets. While the company faces ongoing litigation regarding its New York City "Option Parcel," it continues to prioritize its Megacampus ecosystem strategy, focusing on high-quality, triple-net leased assets to maintain long-term stability despite current macroeconomic and regulatory uncertainties affecting the broader biotechnology industry. |
| Apr 27, 2026 | mda_quarterly | Alexandria Real Estate Equities (ARE) reported a significant turnaround in net income for the first quarter of 2026, reaching $358.9 million, largely driven by a $366.4 million gain on the early extinguishment of debt following a February tender offer to repurchase $1.33 billion in notes. Despite this non-cash gain, total revenues declined 11.5% year-over-year to $671.0 million, and same-property net operating income fell 11.9%. These declines reflect a challenging life science macro environment characterized by a supply glut—with availability rising to 29% in 2025—and a 60% reduction in tenant space requirements since 2021. Consequently, operating occupancy fell to 87.7%. To manage liquidity and leverage, ARE is executing a capital recycling strategy targeting $2.9 billion in dispositions and partial interest sales for 2026 to fund an estimated $1.75 billion in construction spending. Key risks include a prolonged biotech bear market, regulatory uncertainty involving the FDA and NIH, and rising tenant improvement costs and concessions required to remain competitive in high-supply markets such as Greater Boston, the San Francisco Bay Area, and San Diego. |
Source: SEC EDGAR filing text and events; period Aug 14, 2026; filed Aug 14, 2026.
ARE company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.